"Alanine Transaminase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
| Descriptor ID |
D000410
|
| MeSH Number(s) |
D08.811.913.477.700.100
|
| Concept/Terms |
Alanine Transaminase- Alanine Transaminase
- Transaminase, Alanine
- Glutamic-Alanine Transaminase
- Glutamic Alanine Transaminase
- Transaminase, Glutamic-Alanine
- Alanine-2-Oxoglutarate Aminotransferase
- Alanine 2 Oxoglutarate Aminotransferase
- Aminotransferase, Alanine-2-Oxoglutarate
- Alanine Aminotransferase
- Aminotransferase, Alanine
- Glutamic-Pyruvic Transaminase
- Glutamic Pyruvic Transaminase
- Transaminase, Glutamic-Pyruvic
|
Below are MeSH descriptors whose meaning is more general than "Alanine Transaminase".
Below are MeSH descriptors whose meaning is more specific than "Alanine Transaminase".
This graph shows the total number of publications written about "Alanine Transaminase" by people in this website by year, and whether "Alanine Transaminase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alanine Transaminase" by people in Profiles.
-
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025.
-
Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):388-393.
-
Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e34-43.
-
Feasibility of performing multiple point of care testing for HIV anti-retroviral treatment initiation and monitoring from multiple or single fingersticks. PLoS One. 2013; 8(12):e85265.
-
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e55-7.
-
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
-
The prevalence of hepatitis B infection in a rural South African HIV clinic. S Afr Med J. 2011 Jun 27; 101(7):470-1.
-
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20; 375(9719):998-1006.
-
First report of genotype e of hepatitis B virus in an Indian population. Intervirology. 2009; 52(5):235-8.
-
Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther. 2008 Nov; 19(11):1325-31.